In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

David Wallace

Executive Editor

Generics Bulletin Executive Editor Dave Wallace has more than 10 years' experience of reporting on the global generics, biosimilars and value-added medicines industries. Having begun his career in the European chemicals industry, Dave has now spent over a decade with Generics Bulletin, becoming editor from 2018. Bringing his background and education in law to bear on industry litigation as well as national legislative and regulatory affairs, he also keeps a close eye on corporate strategy, personnel moves, and product pipelines. A regular delegate to industry events and conferences, he has a particular interest in local market developments, maintaining close links with national industry representatives. He also organizes and acts as a judge for the annual Global Generics & Biosimilars Award.

Latest From David Wallace

Teva’s Ambwani Switches To Sandoz To Lead European Strategy

Sandoz has recruited Teva’s Karan Ambwani to head up the Novartis unit’s strategy, business development and portfolio in Europe. Meanwhile, Diane DiGangi Trench is moving from Sandoz US to head up the company’s operations in the UK.

Appointments Strategy

India And China Criticized By US Over IP

India and China have once again come under fire from the US over intellectual property protections, in the US Trade Representative’s latest “Special 301” report.

Intellectual Property China

Hikma Introduces A Pair Of US Injectables

Hikma has added to its injectables portfolio in the US with the launches of dexmedetomidine and docetaxel.

Launches Generic Drugs

Hyloris Pushes Into South America With Maxigesic IV

Hyloris is on a roll with licensing deals for its Maxigesic IV non-opioid pain treatment, with an extension of its existing agreement with Pharma Bavaria to cover South American territories coming hot on the heels of recent developments in the US and Europe.

Deals Value-Added Medicines

Australia Extends Biosimilar Education Efforts

Australia’s government has agreed to extend a successful biosimilar education initiative led by the local GBMA industry association.

Australia Biosimilars

Lannett Bets On Respiratory And Insulins Pipeline As Sales Falter

Despite turnover dropping by over a fifth in its financial third quarter, Lannett says it is optimistic that respiratory generics and insulins will offer the firm “durable” opportunities in future. The company has also just reorganized its finances to extend its debt maturity by four years, pushing it back past some of its key launches.

Sales & Earnings Strategy
See All
UsernamePublicRestriction

Register